8	166	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(0, 0), 'end':(0, 9), 'text':'The incidence of well differentiated thyroid cancers in United States'}, {'start':(0, 10), 'end':(0, 17), 'text':'has increased dramatically in the past decade .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(1, 0), 'end':(1, 16), 'text':'Patients with the most common type of thyroid cancer , papillary thyroid cancer ( PTC ) ,'}, {'start':(1, 17), 'end':(1, 26), 'text':'have a low risk of recurrence and high survival .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(2, 0), 'end':(2, 29), 'text':'However , a subset of patients with anaplastic thyroid cancer ( ATC ) present with large invasive tumors and and or metastases , do not respond to any chemotherapeutic regimen'}, {'start':(2, 30), 'end':(2, 35), 'text':'and often die within months .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 10), 'text':'New data are emerging on the genetic or epigenetic changes ,'}, {'label':'comparison', 'direction':'LeftToRight', 'children':[{'start':(3, 11), 'end':(3, 23), 'text':'which seem to contribute to such dramatic worsening of the prognosis in ATC'}, {'start':(3, 24), 'end':(3, 30), 'text':'compared with most other thyroid cancers .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 10), 'text':'Correlative studies have pointed to increased incidence of mortality in patients'}, {'start':(4, 11), 'end':(4, 21), 'text':'who have activating BRAF V600E mutations , , in the mitogen'}]}, {'start':(4, 22), 'end':(4, 24), 'text':'activated protein kinase'}]}, {'start':(4, 25), 'end':(4, 27), 'text':'( MAPK )'}]}, {'start':(4, 28), 'end':(4, 39), 'text':'/ extracellular signal regulated kinase ( ERK ) signaling pathway . ,'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(4, 40), 'end':(4, 40), 'text':'Therapeutics'}, {'start':(4, 41), 'end':(4, 50), 'text':'blocking this signaling pathway are currently in clinical trials .'}]}]}, {'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(5, 0), 'end':(5, 13), 'text':'Although BRAF V600E inhibitors work well in vitro in an anti-proliferative and anti-invasive capacity'}, {'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(5, 14), 'end':(5, 24), 'text':'and effectively reduce tumor volume in vivo in animal models ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 25), 'end':(5, 44), 'text':'they are not capable of inducing apoptosis in thyroid cancer cells . , , Little is known regarding the mechanisms'}, {'start':(5, 45), 'end':(5, 54), 'text':'underlying resistance to apoptosis in these thyroid cancer cells .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'manner-means', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 8), 'text':'Here , we looked at using novel apoptotic agents'}, {'start':(6, 9), 'end':(6, 13), 'text':'to increase thyroid tumor apoptosis'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(6, 14), 'end':(6, 19), 'text':'by activating the death receptor pathway'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(6, 20), 'end':(6, 21), 'text':'and showed'}, {'start':(6, 22), 'end':(6, 36), 'text':'that in some cases combination with anti-BRAF therapies is necessary to fully activate apoptosis .'}]}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 2), 'text':'TNF related apoptosis'}, {'start':(7, 3), 'end':(7, 4), 'text':'inducing ligand'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 5), 'end':(7, 12), 'text':'( TRAIL ) ligand is a promising agent'}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(7, 13), 'end':(7, 20), 'text':'that induces apoptosis in a tumor specific manner'}, {'start':(7, 21), 'end':(7, 38), 'text':'by interacting with specific death domain receptors , TRAIL-R1 ( DR4 ) and TRAIL-R2 ( DR5 ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 14), 'text':'Activation of death domain receptors induces formation of the intracellular cytoplasmic Death Inducing Signaling Complex'}, {'start':(8, 15), 'end':(8, 18), 'text':'( DISC ) ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 19), 'end':(8, 25), 'text':'which directly activates the extrinsic apoptotic pathway'}, {'start':(8, 26), 'end':(8, 36), 'text':'while also crosstalking with the intrinsic pathway through Bid . ,'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 37), 'end':(8, 47), 'text':'Lexatumumab ( HGS-ETR2 ) is a fully humanized agonistic monoclonal antibody'}, {'label':'joint', 'direction':'None', 'children':[{'start':(8, 48), 'end':(8, 52), 'text':'that specifically activates the TRAIL-R2'}, {'start':(8, 53), 'end':(8, 64), 'text':'and has never been tested in thyroid cancer in any capacity .'}]}]}]}, {'start':(9, 0), 'end':(9, 12), 'text':'Lexatumumab is currently in phase I and II trials in advanced malignancy .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 0), 'end':(10, 22), 'text':'This antibody approach has several advantages over the TRAIL ligand itself including improved pharmacokinetics and lack of decoy receptor binding , , ,'}, {'start':(10, 23), 'end':(10, 30), 'text':'although some tumors exhibit resistance to apoptosis .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 48), 'text':'Resistance mechanisms include activation of c-FLICE-like inhibitory protein ( c-FLIP ) , , reduced expression of TRAIL-R2 and TRAIL-R1 receptors on tumor cell surface , overexpression of anti-apoptotic proteins ( Bcl-2 , Bcl-xL and inhibitors of apoptosis ( IAP ) family members ) and reduced expression of pro-apoptotic proteins'}, {'start':(11, 49), 'end':(11, 52), 'text':'( Bax ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(12, 0), 'end':(12, 26), 'text':'Low Bax and Bcl-xL ratio has also been shown to have a critical role in TRAIL resistance . , , Lexatumumab has been combined with various drugs'}, {'start':(12, 27), 'end':(12, 42), 'text':'to overcome resistance to apoptosis in a variety of tumors in vitro and in vivo .'}]}, {'label':'background', 'direction':'RightToLeft', 'children':[{'start':(13, 0), 'end':(13, 11), 'text':'These have included small molecule inhibitors ( lapatanib , cycloheximide ) ,'}, {'start':(13, 12), 'end':(13, 49), 'text':'chemotherapeutic agents ( cisplatin , dacarbazine ) , antiangiogenic factors ( 3TSR ) and also PI3K and MAPK inhibitors . , , , However , no studies of apoptosis with lexatumumab have been performed in thyroid cancer .'}]}]}, {'start':(14, 0), 'end':(14, 7), 'text':'The authors declare no conflict of interest .'}]}]}]}]}
0	1	{'start':(0, 0), 'end':(0, 18), 'text':'Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K and AKT pathways'}
22	95	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(0, 0), 'end':(0, 0), 'text':'Results'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 11), 'text':'Some thyroid cancer cell lines showed exquisite sensitivity to lexatumumab induced apoptosis'}, {'start':(2, 0), 'end':(2, 23), 'text':'Treatment with lexatumumab ( 1000ng and ml ) for 24h resulted in significant apoptosis in three of the five thyroid cancer cell lines .'}]}, {'start':(3, 0), 'end':(3, 15), 'text':'Apoptosis was measured by annexinV and PE staining for the percent of annexinV positive cells .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(4, 0), 'end':(4, 25), 'text':'The cell lines TPC-1 ( 98.6.1+ / -1.0 % , P < 0.001 ) , HTh-7 ( 82.9+ / -15.5 % , P < 0.001 )'}, {'start':(4, 26), 'end':(4, 37), 'text':'and BCPAP ( 82.6+ / -22.3 % , P < 0.01 )'}]}, {'start':(4, 38), 'end':(4, 63), 'text':'showed dramatically higher percentage of apoptosis than the positive control , colon cancer cell line HCT116 ( 38.9+ / -4.6 % , P < 0.01 ;'}]}, {'start':(4, 64), 'end':(4, 65), 'text':') .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 14), 'text':'TPC-1 was the most sensitive to lexatumumab with an IC50 of ~ 194ng and ml'}, {'start':(5, 15), 'end':(5, 35), 'text':'followed by HTh-7 ( ~ 220.4 ng and ml ) and BCPAP ( ~ 401.5 ng and ml ; ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 14), 'text':'Lexatumumab induced apoptosis was confirmed in all three sensitive cell lines by TUNEL staining ,'}, {'label':'cause', 'direction':'LeftToRight', 'children':[{'start':(6, 15), 'end':(6, 26), 'text':'cleavage of caspases-8 / -9 , the effector caspase-3 and PARP ,'}, {'start':(6, 27), 'end':(6, 36), 'text':'thus demonstrating activation of both extrinsic and intrinsic pathways .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 6), 'text':'c-FLIP , the inhibitor of caspase-8 ,'}, {'start':(7, 7), 'end':(7, 13), 'text':'decreased with lexatumumab treatment ( ) .'}]}, {'start':(8, 0), 'end':(8, 19), 'text':'All cell lines had functionally active TRAIL-R2 receptors , with the highest levels present in these sensitive cell lines .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 0), 'end':(9, 24), 'text':'At 8h there was a decrease in the TRAIL-R2 surface receptor after lexatumumab treatment , perhaps due to the high rate of cell death .'}, {'start':(10, 0), 'end':(10, 15), 'text':'Normal thyroid cells , HTori , did not undergo apoptosis with lexatumumab treatment ( ) .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 9), 'text':'Lexatumumab inhibits BCPAP tumor growth in an orthotropic mouse model'}, {'label':'enablement', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 0), 'end':(12, 7), 'text':'To evaluate whether the dramatic effect of lexatumumab'}, {'start':(12, 8), 'end':(12, 20), 'text':'observed in vitro would also result in tumor volume reductions in vivo ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 21), 'end':(12, 28), 'text':'we examined the efficacy of lexatumumab in mice'}, {'start':(12, 29), 'end':(12, 34), 'text':'bearing orthotopically implanted BCPAP tumors .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'explanation', 'direction':'LeftToRight', 'children':[{'start':(13, 0), 'end':(13, 9), 'text':'The BCPAP cell line was chosen for in vivo testing'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(13, 10), 'end':(13, 17), 'text':'because previous experiments in our laboratory have shown'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 18), 'end':(13, 34), 'text':'that the other sensitive cell lines ( TPC-1 , HTh-7 ) do not grow well in mice'}, {'start':(13, 35), 'end':(13, 39), 'text':'( unpublished data ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(14, 0), 'end':(14, 3), 'text':'As previously described ,'}, {'start':(14, 4), 'end':(14, 16), 'text':'BCPAP cells were implanted into the left thyroid lobe of SCID mice .'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 0), 'end':(15, 3), 'text':'Three weeks post implantation'}, {'start':(15, 4), 'end':(15, 15), 'text':'when the tumor volume ranged from ~ 30 to 40mm 3 ,'}]}, {'start':(15, 16), 'end':(15, 25), 'text':'treatment was started twice weekly for 4 weeks total .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 0), 'end':(16, 14), 'text':'Six of the mice were treated with intravenous ( IV ) injections of lexatumumab antibody'}, {'start':(16, 15), 'end':(16, 28), 'text':'( 10mg and kg body weight ) and six with saline ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 0), 'end':(17, 19), 'text':'Four weeks of lexatumumab treatment significantly reduced tumor volume from 204+ / -42.5 to 66.5+ / -26.7 mm 3 ,'}, {'start':(17, 20), 'end':(17, 34), 'text':'( P < 0.001 ) , with a TGI of 67.4 % ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(18, 0), 'end':(18, 4), 'text':'Lexatumumab treated tumors were TTF-1-positive'}, {'label':'joint', 'direction':'None', 'children':[{'start':(18, 5), 'end':(18, 14), 'text':'and showed significantly higher percentage of apoptotic cells by TUNEL'}, {'label':'joint', 'direction':'None', 'children':[{'label':'comparison', 'direction':'LeftToRight', 'children':[{'start':(18, 15), 'end':(18, 18), 'text':'and cleaved caspse-3 staining'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 19), 'end':(18, 21), 'text':'compared with controls'}, {'start':(18, 22), 'end':(18, 36), 'text':'( 14.59+ / -2.16 % versus 2.47+ / -0.6 % , P < 0.001 ;'}]}]}, {'start':(18, 37), 'end':(18, 38), 'text':') .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 0), 'end':(19, 13), 'text':'Of note , there are no lung metastases in this BCPAP orthotopic model .'}, {'label':'explanation', 'direction':'LeftToRight', 'children':[{'start':(20, 0), 'end':(20, 12), 'text':'Some thyroid cancer cell lines were completely resistant to lexatumumab induced apoptosis ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 13), 'end':(20, 17), 'text':'whereas others showed intermediate sensitivity'}, {'label':'joint', 'direction':'None', 'children':[{'start':(21, 0), 'end':(21, 22), 'text':'8505c cells were completely resistant to lexatumumab induced apoptosis ( 4.9+ / -0.9 % ) even at 1000ng and ml ( ) ,'}, {'start':(21, 23), 'end':(21, 39), 'text':'and there was no caspase cascade activation and no apoptotic cells on TUNEL staining ( ) .'}]}]}]}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(22, 0), 'end':(22, 5), 'text':'One other ATC cell line ,'}, {'start':(22, 6), 'end':(22, 41), 'text':'SW1736 ( BRAF V600E ) showed reduced sensitivity to lexatumumab induced apoptosis ( 23.7 % cell death , P < 0.05 ) with some intermediate activation of the extrinsic and intrinsic pathway caspases ( ) .'}]}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(23, 0), 'end':(23, 17), 'text':'Given a high background in annexinV-PE staining in the SW1736 cell line , the MTS assay was used'}, {'start':(23, 18), 'end':(23, 29), 'text':'for determining cell viability in this particular cell line ( ) .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(24, 0), 'end':(24, 17), 'text':'Baseline expression of pro- and anti- apoptotic proteins was different among sensitive and resistant thyroid cancer cell lines'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(24, 18), 'end':(24, 23), 'text':'and was altered with lexatumumab treatment'}, {'start':(25, 0), 'end':(25, 12), 'text':'The baseline expression of pro- and anti-apoptotic proteins was analyzed in detail .'}]}]}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(26, 0), 'end':(26, 4), 'text':'Generally in the cell lines'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(26, 5), 'end':(26, 16), 'text':'that responded with high or intermediate rates of apoptosis to the lexatumumab'}, {'start':(26, 17), 'end':(26, 26), 'text':'( HTh7 , TPC-1 , BCPAP and SW1736 ) ,'}]}]}, {'start':(26, 27), 'end':(26, 47), 'text':'the baseline expression of the pro-apoptotic protein , Bax , was high resulting in a high Bax to Bcl-xL ratio .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(27, 0), 'end':(27, 26), 'text':'The resistant 8505c cells , however , expressed low Bax and high Bcl-xL protein levels , resulting in a low Bax and Bcl-xL ratio ( ) .'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 0), 'end':(28, 15), 'text':'The two sensitive cell lines , HTh7 and TPC-1 , had high baseline pAkt levels ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 16), 'end':(28, 22), 'text':'which rapidly went down with lexatumumab treatment'}, {'start':(28, 23), 'end':(28, 28), 'text':'( result not shown ) ,'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 29), 'end':(28, 43), 'text':'whereas the two cell lines , 8505c and SW1736 , had with high pAkt level'}, {'start':(28, 44), 'end':(28, 52), 'text':'that increased further with lexatumumab treatment ( ) .'}]}]}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(29, 0), 'end':(29, 5), 'text':'BCPAP had low levels of pAkt'}, {'start':(29, 6), 'end':(29, 13), 'text':'that remained low even after lexatumumab treatment .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(30, 0), 'end':(30, 18), 'text':'High pAkt levels contribute to resistance to apoptosis in the SW1736 cell line with intermediate sensitivity to lexatumumab ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(30, 19), 'end':(30, 29), 'text':'and apoptosis can be enhanced by inhibition of the PI3K pathway'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(31, 0), 'end':(31, 14), 'text':'Given the importance of pAkt in contributing to TRAIL resistance in other malignancies , ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(31, 15), 'end':(31, 16), 'text':'we hypothesized'}, {'start':(31, 17), 'end':(31, 41), 'text':'that the high baseline pAkt and the further increased levels with lexatumumab treatment contributed to the SW1736 cells \' intermediate sensitivity to this drug .'}]}]}, {'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(32, 0), 'end':(32, 10), 'text':'While lexatumumab alone triggered a 23 % cell death rate ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(32, 11), 'end':(32, 23), 'text':'addition of the PI3K and pAkt inhibitor , LY294002 ( 50muM ) ,'}, {'start':(32, 24), 'end':(32, 37), 'text':'resulted in a 83.7 % cell death ( P < 0.001 ; ) ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(32, 38), 'end':(32, 40), 'text':'with the cells'}, {'start':(32, 41), 'end':(32, 65), 'text':'showing cleavage of extrinsic and intrinsic caspases 8/9/3 , PARP and the associated Bid protein ( ) even as early as 8h of treatment .'}]}]}]}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(33, 0), 'end':(33, 2), 'text':'Lowering pAkt levels'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(33, 3), 'end':(33, 16), 'text':'caused an increase in both the L&S forms of the pro-apoptotic protein Bim ,'}, {'start':(33, 17), 'end':(33, 28), 'text':'which has been important for initiating TRAIL induced apoptosis ( ) .'}]}]}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(34, 0), 'end':(34, 12), 'text':'The completely resistant 8505c ATC cell line can be triggered to undergo apoptosis'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(34, 13), 'end':(34, 19), 'text':'by inhibiting two important cell survival pathways'}, {'label':'temporal', 'direction':'None', 'children':[{'start':(35, 0), 'end':(35, 24), 'text':'The proliferation of the ATC cell line 8505c is dramatically affected by the BRAF V600E inhibitor PLX4720 both in vitro and in vivo , ,'}, {'start':(35, 25), 'end':(35, 33), 'text':'yet ultimately PLX4720 treatment does not cause apoptosis .'}]}]}]}]}, {'label':'explanation', 'direction':'LeftToRight', 'children':[{'start':(36, 0), 'end':(36, 16), 'text':'This cell line is also completely resistant to direct induction of apoptosis with lexatumumab ( ) .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(37, 0), 'end':(37, 32), 'text':'As the baseline pAkt level is already very high and further increases with either lexatumumab or PLX4720 ( 10muM ) treatment , similar to what we saw in the SW1736 cell line ,'}, {'start':(37, 33), 'end':(37, 36), 'text':'we wanted to test'}]}, {'start':(37, 37), 'end':(37, 46), 'text':'whether the suppression of pAkt alone would trigger apoptosis .'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(38, 0), 'end':(38, 4), 'text':'Furthermore , given previous studies'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(38, 5), 'end':(38, 27), 'text':'emphasizing the crosstalk between the MAPK and PI3K cell survival pathways in promoting resistance to apoptosis , , , we chose to study'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(38, 28), 'end':(38, 38), 'text':'whether dual targeting of these pathways could overcome the severe resistance'}, {'start':(38, 39), 'end':(38, 47), 'text':'that 8505c cells have to lexatumumab induced apoptosis .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(39, 0), 'end':(39, 14), 'text':'Therefore , three drugs were used singly or in combination to test our hypothesis :'}, {'start':(39, 15), 'end':(39, 39), 'text':'the MAPK and BRAF V600E inhibitor , PLX4720 ( 10muM ) , PI3K and pAkt inhibitor , LY294002 ( 50muM ) , and lexatumumab .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(40, 0), 'end':(40, 13), 'text':'No drug alone induced apoptosis in 8505c cells with the percentage of apoptotic cells'}, {'start':(40, 14), 'end':(40, 25), 'text':'ranging from 4.9+ / -0.9 % ( lexatumumab ) to 5.5+ /'}]}, {'start':(40, 26), 'end':(40, 34), 'text':'-1.5 % ( PLX4720 ( 10muM ) ) .'}]}, {'label':'contrast', 'direction':'RightToLeft', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(41, 0), 'end':(41, 12), 'text':'Dual inhibition with the MAPK and PI3K inhibitors ( PLX4720 and LY294002 )'}, {'start':(41, 13), 'end':(41, 28), 'text':'without the apoptotic agent also did not boost apoptosis ( 5.9+ / -4.2 % ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(42, 0), 'end':(42, 18), 'text':'However , combining lexatumumab with the inhibitors of either of the two pathways did result in increased apoptosis .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(43, 0), 'end':(43, 19), 'text':'Dual combination of lexatumumab and LY294002 increased apoptosis to 33.1+ / -13.2 % , P < 0.01 ( ) ,'}, {'start':(43, 20), 'end':(43, 41), 'text':'whereas the dual combination with PLX4720 caused a moderate increase in apoptosis to 20.9+ / -3.6 % , P < 0.01 .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(44, 0), 'end':(44, 11), 'text':'Combining all three drugs together , however , resulted in dramatic apoptosis'}, {'start':(44, 12), 'end':(44, 21), 'text':'( 72.1+ / -3.2 % , P < 0.001 ;'}]}, {'start':(44, 22), 'end':(44, 29), 'text':') and strong TUNEL staining ( ) .'}]}]}]}]}]}]}]}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(45, 0), 'end':(45, 3), 'text':'Dosing curves were used'}, {'label':'joint', 'direction':'None', 'children':[{'start':(45, 4), 'end':(45, 7), 'text':'to calculate optimal dosage'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(45, 8), 'end':(45, 9), 'text':'and showed'}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(45, 10), 'end':(45, 33), 'text':'that combining these three drugs together allowed a much lower dose of lexatumumab ( IC50 of 200ng and ml , data not shown )'}, {'start':(45, 34), 'end':(45, 49), 'text':'to be effective at inducing apoptosis with maximal apoptosis at 500ng and ml ( ) .'}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(46, 0), 'end':(46, 10), 'text':'Analysis of the pro- and anti-apoptotic pathway proteins in 8505c cells'}, {'start':(46, 11), 'end':(46, 19), 'text':'treated with the combination of all three drugs :'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(46, 20), 'end':(46, 24), 'text':'PLX4720 ( 10muM ) ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(46, 25), 'end':(46, 42), 'text':'LY294002 ( 50muM ) and lexatumumab ( 1000ng and ml ) in 8505c cells showed ( ) :'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(47, 0), 'end':(47, 20), 'text':'Activation of all extrinsic and intrinsic pathways with significant cleavage of caspase-8 / -9 / -3 and PARP ( ) .'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(48, 0), 'end':(48, 8), 'text':'( b ) Activation of the pro-apoptotic proteins :'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(48, 9), 'end':(48, 11), 'text':'cleavage of Bid'}, {'start':(48, 12), 'end':(48, 20), 'text':'( indicated by the decrease of pro-Bid protein ;'}]}, {'start':(48, 21), 'end':(48, 40), 'text':') and increased expression of Bad , Bak , Bim ( BimL and BimS ) and Bax ( ) .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'explanation', 'direction':'LeftToRight', 'children':[{'start':(49, 0), 'end':(49, 9), 'text':'The Bim expression was highest after 24h of treatment ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(49, 10), 'end':(49, 11), 'text':'whereas Bax'}, {'start':(49, 12), 'end':(49, 26), 'text':'increased in expression after 1h and then remained stably elevated till 24h ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(50, 0), 'end':(50, 13), 'text':'( c ) Dramatic decrease in anti-apoptotic proteins - Bcl-xL , Mcl-1and c-FLIP -'}, {'label':'joint', 'direction':'None', 'children':[{'start':(50, 14), 'end':(50, 28), 'text':'( ) were reduced with treatment , even as early as after 2h of treatment'}, {'start':(50, 29), 'end':(50, 37), 'text':'and remained so up to 48h ( ) .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(51, 0), 'end':(51, 16), 'text':'TRAIL-R2 expression , on the other hand , increased immediately after the treatment for a short time'}, {'start':(51, 17), 'end':(51, 25), 'text':'and then progressively decreased by 48h ( ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(52, 0), 'end':(52, 14), 'text':'Bcl-xL has a significant role in the resistance of 8505c cells to induction of apoptosis'}, {'start':(53, 0), 'end':(53, 18), 'text':'Our results with the three drug combination confirms the work of other authors in various other malignant lines ,'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(53, 19), 'end':(53, 19), 'text':'indicating'}, {'start':(53, 20), 'end':(53, 44), 'text':'that decreased expression of anti-apoptotic protein Bcl-xL is critical in initiation and maintenance of a robust apoptotic response to TRAIL . , , , ,'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(53, 45), 'end':(53, 57), 'text':'The 8505c cells started with a very high baseline Bcl-xL protein level ,'}, {'start':(53, 58), 'end':(53, 71), 'text':'which was reduced significantly after transfection with Bcl-xL siRNA for 48h ( ) .'}]}]}]}]}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(54, 0), 'end':(54, 11), 'text':'Subsequent treatment of these cells with lexatumumab ( 1000ng and ml )'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(54, 12), 'end':(54, 16), 'text':'resulted in 52.3 % apoptosis'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(54, 17), 'end':(54, 29), 'text':'as measured by annexinV-PE staining as well as caspase 3 and PARP cleavages'}, {'label':'joint', 'direction':'None', 'children':[{'start':(54, 30), 'end':(54, 38), 'text':'compared with lexatumumab controls ( 3.4 % apoptosis )'}, {'start':(54, 39), 'end':(54, 46), 'text':'or scrambled siRNA ( 8.4 % ) .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(55, 0), 'end':(55, 7), 'text':'Dual inhibition of pAkt and MAPK pathways increases'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(55, 8), 'end':(55, 16), 'text':'the lexatumumab induced apoptosis in 8505c orthotopic thyroid model'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(56, 0), 'end':(56, 8), 'text':'On the basis of our in vitro results ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(56, 9), 'end':(56, 10), 'text':'we predicted'}, {'start':(56, 11), 'end':(56, 36), 'text':'that the three drug combination would result in tumor apoptosis in an 8505c thyroid orthotopic model of aggressive thyroid cancer with wide spread lung metastases .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(57, 0), 'end':(57, 9), 'text':'Treatment was initiated 2 weeks post-orthotopic implantation of 8505c-GFP cells'}, {'start':(57, 10), 'end':(57, 62), 'text':'and continued for 2 weeks with either lexatumumab ( 5mg and kg body weight , IV twice a week ) , PLX4720 ( 417mg and kg chow diet ) , LY294002 ( 50mg and kg body weight , IP twice a week ) or a combination of all three drugs ( ) .'}]}]}]}]}, {'start':(58, 0), 'end':(58, 6), 'text':'Controls received normal chow and saline .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(59, 0), 'end':(59, 1), 'text':'Results showed'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(59, 2), 'end':(59, 7), 'text':'that 4 weeks post-tumor implantation ,'}, {'label':'comparison', 'direction':'LeftToRight', 'children':[{'start':(59, 8), 'end':(59, 41), 'text':'treatment with lexatumumab alone ( 76.8+ / -15.2 mm 3 ) and LY294002 alone ( 72.5+ / -12.0 mm 3 ) did not result in a statistically significant decrease in tumor volume or metastasis'}, {'start':(59, 42), 'end':(59, 54), 'text':'as compared with control ( 91.2+ / -20.6 mm 3 ; ) .'}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(60, 0), 'end':(60, 1), 'text':'We confirmed'}, {'label':'joint', 'direction':'None', 'children':[{'start':(60, 2), 'end':(60, 11), 'text':'that PLX4720 alone reduced primary tumor volume by 95 %'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(60, 12), 'end':(60, 17), 'text':'and completely treated the lung metastases'}, {'start':(60, 18), 'end':(60, 21), 'text':'compared with controls .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(61, 0), 'end':(61, 11), 'text':'PLX4720 treatment in vivo only resulted in < 4 % of cells'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(61, 12), 'end':(61, 17), 'text':'showing cleaved caspase-3 by IHC ,'}, {'start':(61, 18), 'end':(61, 26), 'text':'which was not significantly increased compared with controls .'}]}]}, {'start':(62, 0), 'end':(62, 30), 'text':'The three drug combination resulted in 99 % reduction in primary tumor volume , complete disappearance of lung metastases and elevated cleaved caspase 3 levels to 14+ / -2 % .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(63, 0), 'end':(63, 17), 'text':'All the tumors in the control group and the treated groups stained positive for TTF-1 ( ) .'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(64, 0), 'end':(64, 1), 'text':'It seemed'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(64, 2), 'end':(64, 3), 'text':'that ,'}, {'label':'contrast', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(64, 4), 'end':(64, 24), 'text':'while the reduction in the primary tumor volume was statistically no different between PLX4720 alone and the three drug combination ,'}, {'start':(64, 25), 'end':(64, 33), 'text':'given the dramatic tumor reductions in both scenarios ,'}]}, {'start':(64, 34), 'end':(64, 44), 'text':'apoptosis was clearly only triggered with the three drug combination .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(65, 0), 'end':(65, 14), 'text':'Human PTC expression profiling of apoptotic genes show a pattern of potential sensitivity to lexatumumab'}, {'label':'condition', 'direction':'RightToLeft', 'children':[{'start':(66, 0), 'end':(66, 13), 'text':'If TRAIL based therapies are to be attempted in patients with thyroid cancer ,'}, {'label':'comparison', 'direction':'LeftToRight', 'children':[{'start':(66, 14), 'end':(66, 36), 'text':'it is important to understand the basal expression of various apoptotic and death receptor gene expression profiles in thyroid cancer patient samples ,'}, {'start':(66, 37), 'end':(66, 42), 'text':'compared with normal thyroid samples .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(67, 0), 'end':(67, 14), 'text':'Using microarray genomic data from PTC and normal thyroid samples by Giordano et al. ,'}, {'start':(67, 15), 'end':(67, 22), 'text':'we analyzed 75 genes related to apoptosis :'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(67, 23), 'end':(67, 27), 'text':'two of these decreased ,'}, {'start':(67, 28), 'end':(67, 42), 'text':'whereas seven increased in expression by at least twofold ( P < 0.001 ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(68, 0), 'end':(68, 20), 'text':'Expression profiles for five of these genes were then confirmed by RT-PCR in a cohort of 10 human PTCs and four'}, {'start':(68, 21), 'end':(68, 25), 'text':'matched normal thyroid tissues .'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(69, 0), 'end':(69, 0), 'text':'Those'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(69, 1), 'end':(69, 12), 'text':'that showed more than a twofold difference in relative values of comparisons'}, {'start':(69, 13), 'end':(69, 17), 'text':'( P < 0.05 )'}]}]}, {'start':(69, 18), 'end':(69, 22), 'text':'were considered differentially expressed .'}]}]}]}]}]}]}, {'label':'contrast', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'comparison', 'direction':'LeftToRight', 'children':[{'start':(70, 0), 'end':(70, 12), 'text':'Four of the five genes had higher relative mRNA expressions in PTC samples'}, {'start':(70, 13), 'end':(70, 33), 'text':'compared with the matched normal thyroids - TRAIL-R2 ( ~ 3.2+ / -1.4 - fold change , P < 0.05 ;'}]}, {'start':(70, 34), 'end':(70, 50), 'text':') , Bax ( ~ 3.0+ / -2.5 - fold change , P < = 0.05 ;'}]}, {'start':(70, 51), 'end':(70, 66), 'text':') , Bcl-xL ( ~ 2.7+ / -0.5 - fold change , P < 0.01 ;'}]}, {'start':(70, 67), 'end':(70, 82), 'text':') and Bid ( ~ 8.2+ / -2.5 - fold change , P < 0.001 ;'}]}, {'start':(70, 83), 'end':(70, 84), 'text':') .'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(71, 0), 'end':(71, 15), 'text':'In contrast , Bim ( 2.9+ / -0.92 - fold change , P < 0.01 ;'}, {'start':(71, 16), 'end':(71, 16), 'text':')'}]}, {'start':(71, 17), 'end':(71, 31), 'text':'showed a significant decrease in levels between the PTC patient tumors and normal thyroids .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(72, 0), 'end':(72, 5), 'text':'This pattern is similar to that'}, {'start':(72, 6), 'end':(72, 13), 'text':'seen in the sensitive BCPAP cell line .'}]}]}]}
1	8	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 12), 'text':'Current treatment for recurrent and aggressive and anaplastic thyroid cancers is ineffective .'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 2), 'text':'Novel targeted therapies'}, {'label':'contrast', 'direction':'None', 'children':[{'start':(1, 3), 'end':(1, 20), 'text':'aimed at the inhibition of the mutated oncoprotein BRAF V600E have shown promise in vivo and in vitro'}, {'start':(1, 21), 'end':(1, 28), 'text':'but do not result in cellular apoptosis .'}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 2), 'text':'TNF related apoptosis'}, {'start':(2, 3), 'end':(2, 4), 'text':'inducing ligand'}]}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(2, 5), 'end':(2, 14), 'text':'( TRAIL ) induces apoptosis in a tumor selective manner'}, {'start':(2, 15), 'end':(2, 21), 'text':'by activating the extrinsic apoptotic pathway .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(3, 0), 'end':(3, 3), 'text':'Here , we show'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 4), 'end':(3, 20), 'text':'that a TRAIL-R2 agonist antibody , lexatumumab , induces apoptosis effectively in some thyroid cancer cell lines'}, {'start':(3, 21), 'end':(3, 28), 'text':'( HTh-7 , TPC-1 and BCPAP ) ,'}]}, {'start':(3, 29), 'end':(3, 42), 'text':'while more aggressive anaplastic cell lines ( 8505c and SW1736 ) show resistance .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(4, 0), 'end':(4, 21), 'text':'Treatment of the most resistant cell line , 8505c , using lexatumumab in combination with the BRAF V600E inhibitor , PLX4720 ,'}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(4, 22), 'end':(4, 35), 'text':'and the PI3K inhibitor , LY294002 , ( triple-drug combination ) sensitizes the cells'}, {'start':(4, 36), 'end':(4, 56), 'text':'by triggering both the extrinsic and intrinsic apoptotic pathways in vitro as well as 8505c orthotopic thyroid tumors in vivo .'}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 13), 'text':'A decrease in anti-apoptotic proteins , pAkt , Bcl-xL , Mcl-1 and c-FLIP ,'}, {'start':(5, 14), 'end':(5, 26), 'text':'coupled with an increase in the activator proteins , Bax and Bim ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 27), 'end':(5, 36), 'text':'results in an increase in the Bax to Bcl-xL ratio'}, {'start':(5, 37), 'end':(5, 51), 'text':'that appears to be critical for sensitization and subsequent apoptosis of these resistant cells .'}]}]}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(6, 0), 'end':(6, 2), 'text':'Our results suggest'}, {'label':'contrast', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 3), 'end':(6, 16), 'text':'that targeting the death receptor pathway in thyroid cancer can be a promising strategy'}, {'start':(6, 17), 'end':(6, 24), 'text':'for inducing apoptosis in thyroid cancer cells ,'}]}, {'start':(6, 25), 'end':(6, 45), 'text':'although combination with other kinase inhibitors may be needed in some of the more aggressive tumors initially resistant to apoptosis .'}]}]}]}
167	169	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 1), 'text':'Supplementary Results'}, {'start':(1, 0), 'end':(1, 6), 'text':'Click here for additional data file .'}]}
166	167	{'start':(0, 0), 'end':(0, 1), 'text':'Supplementary Material'}
132	165	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 2), 'text':'Materials and methods'}, {'label':'textual-organization', 'direction':'None', 'children':[{'start':(1, 0), 'end':(1, 5), 'text':'Cell culture , antibodies and reagents'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 4), 'text':'Reagents included the following :'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 5), 'end':(2, 19), 'text':'lexatumumab ( Human Genome Sciences , GlaxoSmithKline , Philadelphia , PA , USA ) ,'}, {'start':(2, 20), 'end':(2, 43), 'text':'LY294002 ( Cell Signaling Technology , Danvers , MA , USA ) and PLX4720 ( Plexxikon , Berkeley , CA , USA ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 12), 'text':'Antibodies - beta-actin , phospho-p44 / 42 MAPK ( ERK1 and 2 )'}, {'start':(3, 13), 'end':(3, 17), 'text':'( Thr202 and Tyr204 )'}]}, {'start':(3, 18), 'end':(3, 30), 'text':'( phospho-ERK ) , p44 and 42 MAPK ( ERK1 and 2 )'}]}, {'start':(3, 31), 'end':(3, 44), 'text':'( Total ERK ) , total Akt , phospho-Akt ( Ser 473 ) ,'}]}, {'start':(3, 45), 'end':(3, 47), 'text':'caspases 3,8,9 ,'}]}, {'start':(3, 48), 'end':(3, 71), 'text':'cleaved caspase-3 , PARP , c-FLIP , TRAIL-R2 , Bcl2 , Bcl-xL , Mcl-1 , Bim , Bid , Bax , Bad , Bak'}]}, {'start':(3, 72), 'end':(3, 78), 'text':'were purchased from Cell Signaling Technology .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(4, 0), 'end':(4, 24), 'text':'ATC cell lines - 8505c ( BRAF V600E /- ) , SW1736 ( BRAF V600E and wt ) , HTh-7 ( NRAS Q61R ) ;'}, {'label':'joint', 'direction':'None', 'children':[{'start':(4, 25), 'end':(4, 44), 'text':'PTC cell lines - BCPAP ( BRAF V600E and wt ) , TPC-1 ( RET and PTC -1 ) ;'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 45), 'end':(4, 67), 'text':'and normal thyroid cell line - HTori were grown in RPMI1640 medium with 10 % FBS and Penicillin ( 100units and ml )'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 68), 'end':(4, 74), 'text':'/ streptomycin ( 100mug and ml )'}, {'start':(4, 75), 'end':(4, 85), 'text':'( Gibco , Grand Island , NY , USA ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 4), 'text':'Apoptosis assays and western blots'}, {'start':(6, 0), 'end':(6, 8), 'text':'Treatment was carried out at 60-70 % confluency .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 17), 'text':'BCPAP , HTh-7 and TPC-1 cells were treated with lexatumumab ( 1000ng and ml ) for 24h ,'}, {'start':(7, 18), 'end':(7, 43), 'text':'whereas 8505c and SW1736 cells received treatment with lexatumumab alone or in combination with LY294002 ( 50muM ) and PLX4720 ( 10muM ) for 48h .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 27), 'text':'The percent of apoptotic cells was assayed by flow cytometry ( BD Sorp 8 Laser LSR II ( BD Biosciences , San Jose , CA , USA )'}, {'start':(8, 28), 'end':(8, 37), 'text':'using annexinV-PE Apoptosis Detection Kit ( BD Biosciences ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(9, 0), 'end':(9, 4), 'text':'Flow cytometry data were analyzed'}, {'start':(9, 5), 'end':(9, 18), 'text':'using FlowJo ( Tree Star Inc. , Ashland , OR , USA ) .'}]}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(10, 0), 'end':(10, 27), 'text':'For determining the IC50 and response curves of lexatumumab , 10000 cells were treated with a wide range of lexatumumab concentrations for 72h and cell viability was tested'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 28), 'end':(10, 37), 'text':'using CellTiter96 Aqueous One Solution Reagent for the MTS assay'}, {'start':(10, 38), 'end':(10, 47), 'text':'( Promega , Madison , WI , USA ) .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 8), 'text':'For terminal deoxynucleotidyl transferase mediated dUTP nick end labeling'}, {'start':(11, 9), 'end':(11, 23), 'text':'( TUNEL ) assay , cells were fixed with 1 % paraformaldehyde in cold PBS'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 24), 'end':(11, 30), 'text':'and processed using the APO-BrdU TUNEL kit'}, {'start':(11, 31), 'end':(11, 41), 'text':'( Invitrogen , Grand Island , NY , USA ) ,'}]}]}, {'start':(11, 42), 'end':(11, 49), 'text':'and apoptotic cells were counted using fluorescence .'}]}]}]}]}, {'start':(12, 0), 'end':(12, 19), 'text':'For western blot analysis , all the drug treatments were carried out for 8h at 60-70 % cell confluency .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 0), 'end':(13, 15), 'text':'At the end of the treatment , the cells were lysed on ice in RIPA buffer'}, {'start':(13, 16), 'end':(13, 32), 'text':'containing protease and phosphatase inhibitor cocktail ( Thermo Scientific , Rockford , IL , USA ) .'}]}, {'start':(14, 0), 'end':(14, 8), 'text':'Western blot assay was performed using standard procedure .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 0), 'end':(15, 1), 'text':'siRNA knockdown'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(16, 0), 'end':(16, 20), 'text':'A total of 1 x 10 5 8505c cells were transfected with either 50nM of Bcl-xL siRNA ( siGENOME SMARTpool )'}, {'start':(16, 21), 'end':(16, 32), 'text':'or scrambled siRNA ( Dharmacon and Thermo Fisher Scientific Inc. ) ,'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(16, 33), 'end':(16, 34), 'text':'using Dharmafect2'}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(16, 35), 'end':(16, 38), 'text':'and incubated for 48h'}, {'start':(16, 39), 'end':(16, 44), 'text':'to achieve Bcl-xL protein knockdown .'}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(17, 0), 'end':(17, 12), 'text':'Cells were then treated with lexatumumab ( 1000ng and ml ) for 24h'}, {'start':(17, 13), 'end':(17, 17), 'text':'and assayed for apoptosis .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 0), 'end':(18, 1), 'text':'Real-time PCR'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 0), 'end':(19, 21), 'text':'Real-time PCR was performed and analyzed using Lightcycler 96 ( Roche ) qPCR machine and its software , normalized to GAPDH expression'}, {'start':(19, 22), 'end':(19, 25), 'text':'as described previously .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 0), 'end':(20, 3), 'text':'Primer sequences include :'}, {'start':(20, 4), 'end':(20, 8), 'text':'TRAIL-R2 ( forward ) :'}]}, {'start':(20, 9), 'end':(20, 18), 'text':'5 \' - ACCACGACCAGAAACACAG-3 \' and ( reverse ) :'}]}, {'start':(20, 19), 'end':(20, 28), 'text':'5 \' - CATTCGATGTCACTCCAGGG-3 \' Bcl-xL ( forward ) :'}]}, {'start':(20, 29), 'end':(20, 38), 'text':'5 \' - GTGGAAAGCGTAGACAAGGAG-3 \' and ( reverse ) :'}]}, {'start':(20, 39), 'end':(20, 48), 'text':'5 \' - CTGCATTGTTCCCATAGAGTTC-3 \' Bax ( forward ) :'}]}, {'start':(20, 49), 'end':(20, 58), 'text':'5 \' - AGTAACATGGAGCTGCAGAG-3 \' and ( reverse ) :'}]}, {'start':(20, 59), 'end':(20, 68), 'text':'5 \' - AGTAGAAAAGGGCGACAACC-3 \' Bid ( forward ) :'}]}, {'start':(20, 69), 'end':(20, 78), 'text':'5 \' - ATTAACCAGAACCTACGCACC-3 \' and ( reverse ) :'}]}, {'start':(20, 79), 'end':(20, 88), 'text':'5 \' - TGACCACATCGAGCTTTAGC-3 \' Bim ( forward ) :'}]}, {'start':(20, 89), 'end':(20, 98), 'text':'5 \' - TCGGACTGAGAAACGCAAG-3 \' and ( reverse ) :'}]}, {'start':(20, 99), 'end':(20, 104), 'text':'5 \' - CTCGGTCACACTCAGAACTTAC-3 \' .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 0), 'end':(21, 6), 'text':'Orthotopic thyroid cancer model and pathologic analysis'}, {'start':(22, 0), 'end':(22, 20), 'text':'All animal work was conducted at the Massachusetts General Hospital in accordance with the federal , local and institutional guidelines .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(23, 0), 'end':(23, 15), 'text':'For orthotopic tumor implantations , 10-week-old female SCID mice were injected with 10 6 tumor cells'}, {'start':(23, 16), 'end':(23, 19), 'text':'as previously described :'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(23, 20), 'end':(23, 24), 'text':'12 animals had BCPAP cells'}, {'start':(23, 25), 'end':(23, 31), 'text':'implanted ( 6 and group ) ,'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(23, 32), 'end':(23, 38), 'text':'and 40 animals had 8505c-GFP cells injected'}, {'start':(23, 39), 'end':(23, 44), 'text':'( 8 and group ) .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(24, 0), 'end':(24, 9), 'text':'At the end of treatment , the mice were killed'}, {'start':(24, 10), 'end':(24, 28), 'text':'and the tumor volume was calculated as ( pi and 6 ) x length x width x height .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(25, 0), 'end':(25, 2), 'text':'Tumor growth inhibition'}, {'start':(25, 3), 'end':(25, 9), 'text':'( TGI ) was determined using :'}]}, {'start':(25, 10), 'end':(25, 19), 'text':'TGI = ( 1-treatment and control ) x 100 .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(26, 0), 'end':(26, 16), 'text':'GFP imaging was performed using multispectral fluorescence scanner ( CRi Maestro 500 , CRi Inc. ) .'}, {'label':'joint', 'direction':'None', 'children':[{'start':(27, 0), 'end':(27, 12), 'text':'Tumors were collected in 10 % formalin for H&E , TUNEL , TTF-1'}, {'start':(27, 13), 'end':(27, 16), 'text':'and cleaved caspase-3 .'}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 0), 'end':(28, 3), 'text':'In case of mice'}, {'start':(28, 4), 'end':(28, 8), 'text':'injected with 8505c-GFP cells ,'}]}, {'start':(28, 9), 'end':(28, 23), 'text':'the tumors were collected at the end of 1-week treatment for the IHC analysis .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(29, 0), 'end':(29, 1), 'text':'Statistical analysis'}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(30, 0), 'end':(30, 4), 'text':'Statistical analysis was carried out'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(30, 5), 'end':(30, 7), 'text':'using Microsoft Excel'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(30, 8), 'end':(30, 19), 'text':'( Microsoft , Redmond , VA , USA ) and GraphPad Prism'}, {'start':(30, 20), 'end':(30, 30), 'text':'( GraphPad , La Jolla , CA , USA ) .'}]}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(31, 0), 'end':(31, 8), 'text':'All experiments were performed at least three times ,'}, {'start':(31, 9), 'end':(31, 22), 'text':'and the results were expressed as mean+ /- S.D. of the individual experiments .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(32, 0), 'end':(32, 6), 'text':'Results were compared using the unpaired ,'}, {'start':(32, 7), 'end':(32, 12), 'text':'two tailed Student \'s t-test ;'}]}, {'start':(32, 13), 'end':(32, 31), 'text':'P-values of < 0.05 were considered significant ( * P < 0.01 , ** P < 0.001 ) .'}]}]}]}
95	132	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(0, 0), 'end':(0, 0), 'text':'Discussion'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 9), 'text':'Aggressive thyroid cancers remain resistant to traditional chemotherapeutic agents .'}, {'label':'joint', 'direction':'None', 'children':[{'start':(2, 0), 'end':(2, 17), 'text':'Novel targeted therapies are being tested in the preclinical and clinical setting for the last 5 years .'}, {'label':'joint', 'direction':'None', 'children':[{'start':(3, 0), 'end':(3, 10), 'text':'Effort has been mostly focused on multikinase inhibitors such as sorafenib'}, {'start':(3, 11), 'end':(3, 18), 'text':'or targeting the BRAF or MEK pathways .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(4, 0), 'end':(4, 0), 'text':'Agents'}, {'start':(4, 1), 'end':(4, 11), 'text':'triggering apoptosis have not been well studied in thyroid cancer .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 32), 'text':'We report here for the first time the efficacy of the pro-apoptotic TRAIL-receptor 2 agonist , lexatumumab , in inducing apoptosis in a variety of representative thyroid cancer cells with well defined mutations'}, {'start':(5, 33), 'end':(5, 57), 'text':'that include BRAF V600E ( BCPAP , 8505c , SW1736 ) , NRAS Q61R ( HTh-7 ) and RET and PTC ( TPC-1 ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'cause', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 14), 'text':'We observed a range of apoptotic responses to lexatumumab , with some being exquisitely sensitive'}, {'start':(6, 15), 'end':(6, 22), 'text':'( TPC-1 , HTh-7 and BCPAP ) ,'}]}, {'start':(6, 23), 'end':(6, 35), 'text':'whereas others were moderately or completely resistant ( SW1736 and 8505c ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 15), 'text':'Interestingly , the mutational status alone did not show a direct correlation to lexatumumab sensitivity .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(8, 0), 'end':(8, 4), 'text':'When exposed to lexatumumab ,'}, {'start':(8, 5), 'end':(8, 22), 'text':'the sensitive cell lines were able to efficiently and rapidly activate both extrinsic and intrinsic apoptotic pathways .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 0), 'end':(9, 6), 'text':'As there was a strong apoptotic response'}, {'start':(9, 7), 'end':(9, 19), 'text':'ranging from 83 to 99 % in the three sensitive cell lines ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 20), 'end':(9, 37), 'text':'we tested the in vivo efficacy of this novel antibody in an orthotopic animal model of thyroid cancer'}, {'start':(9, 38), 'end':(9, 47), 'text':'using one of the sensitive cell lines , BCPAP .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(10, 0), 'end':(10, 2), 'text':'Our results showed'}, {'label':'cause', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 3), 'end':(10, 11), 'text':'that lexatumumab treatment alone induced apoptosis in vivo ,'}, {'start':(10, 12), 'end':(10, 21), 'text':'which resulted in effective tumor shrinkage of 67 % ,'}]}, {'start':(10, 22), 'end':(10, 36), 'text':'indicating the potential utility of this agent in some patients with papillary or ATCs .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 6), 'text':'Furthermore , expression profiling of five genes'}, {'start':(11, 7), 'end':(11, 18), 'text':'known to be important in regulating the apoptotic response to lexatumumab showed'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 19), 'end':(11, 28), 'text':'that all 10 PTC samples directly from patients had profiles'}, {'start':(11, 29), 'end':(11, 38), 'text':'that were similar to the BCPAP PTC cell line ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 39), 'end':(11, 49), 'text':'which we have shown here to be exquisitely sensitive to TRAIL'}, {'start':(11, 50), 'end':(11, 52), 'text':'induced apoptosis .'}]}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(12, 0), 'end':(12, 8), 'text':'Not surprisingly , the most aggressive ATC cell line'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 9), 'end':(12, 24), 'text':'we studied , 8505c , showed remarkable resistance to apoptosis with < 5 % of cells'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 25), 'end':(12, 26), 'text':'undergoing apoptosis'}, {'start':(12, 27), 'end':(12, 35), 'text':'even when exposed to high doses of lexatumumab .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 0), 'end':(13, 7), 'text':'These data are consistent with our previous studies'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 8), 'end':(13, 8), 'text':'showing'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'LeftToRight', 'children':[{'start':(13, 9), 'end':(13, 17), 'text':'that this cell line is generally resistant to apoptosis'}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(13, 18), 'end':(13, 36), 'text':'when treated with other agents . , , We were able to induce apoptosis in this resistant cell line'}, {'start':(13, 37), 'end':(13, 53), 'text':'by combining lexatumumab with a PI3K and Akt inhibitor LY294002 and a BRAF V600E inhibitor PLX4720 .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 0), 'end':(14, 2), 'text':'Our combinatorial strategy'}, {'start':(14, 3), 'end':(14, 24), 'text':'that was guided by known signaling pathway and genomic data led to rapid and sustained apoptosis in vitro and in vivo .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(15, 0), 'end':(15, 12), 'text':'Although PLX4720 alone effectively reduced the tumor volume and the lung metastasis ,'}, {'start':(15, 13), 'end':(15, 24), 'text':'it failed to induce apoptosis in the tumor cells in vivo .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'LeftToRight', 'children':[{'start':(16, 0), 'end':(16, 8), 'text':'Development of resistance to PLX4720 is a major limitation'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 9), 'end':(16, 13), 'text':'when it comes to efficacy'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 14), 'end':(16, 16), 'text':'in treating patients'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 17), 'end':(16, 26), 'text':'as recurrent tumor growth occurs from the few remaining cells'}, {'start':(16, 27), 'end':(16, 32), 'text':'that have not undergone apoptosis .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 0), 'end':(17, 9), 'text':'This study points to the utility of the three-drug combination'}, {'start':(17, 10), 'end':(17, 29), 'text':'in inducing apoptosis in the 8505c orthotopic tumors along with the rapid tumor shrinkage and reduction of lung metastasis .'}]}]}, {'start':(18, 0), 'end':(18, 10), 'text':'This study among others can lead to better long-term outcomes .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(19, 0), 'end':(19, 2), 'text':'Our data showed'}, {'start':(19, 3), 'end':(19, 22), 'text':'that two critical elements had a role in the marked resistance to apoptosis in this cell line ( ) .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(20, 0), 'end':(20, 24), 'text':'The 8505c cells had both a very high baseline expression of Bcl-xL and a low expression of Bax ( low Bax and Bcl-xL ratio )'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(20, 25), 'end':(20, 25), 'text':'and'}, {'start':(20, 26), 'end':(20, 38), 'text':'when exposed to lexatumumab treatment mounted a remarkable increase in pAkt levels .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'condition', 'direction':'RightToLeft', 'children':[{'start':(21, 0), 'end':(21, 7), 'text':'As pAkt is a well-known anti-apoptotic protein ,'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(21, 8), 'end':(21, 12), 'text':'a sudden increase in pAkt'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 13), 'end':(21, 28), 'text':'when exposed to the apoptotic agent is in sharp contrast to the sensitive cell lines ,'}, {'start':(21, 29), 'end':(21, 35), 'text':'which show suppression of pAkt levels .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(22, 0), 'end':(22, 24), 'text':'Inhibition of pAkt by LY294002 or knockdown of Bax and Bcl-xL protein ratio alone did somewhat increase the apoptotic response to 30 % however ,'}, {'start':(22, 25), 'end':(22, 45), 'text':'only when the three-drug combination was used were these cells able to mount an apoptotic response up to 68 % .'}]}, {'start':(23, 0), 'end':(23, 19), 'text':'The \' crosstalk \' between apoptotic and various kinase pathways is just starting to be studied in other malignancies .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'cause', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(24, 0), 'end':(24, 29), 'text':'In colorectal cancer , resistance to apoptosis is thought to be due to dual mutations in the PI3 and MAP Kinase pathways ( PIK3CA H1047 and BRAF V600E ) ,'}, {'start':(24, 30), 'end':(24, 36), 'text':'which cause high levels of pAkt ,'}]}, {'start':(24, 37), 'end':(24, 42), 'text':'thus blocking TRAIL induced apoptosis .'}]}, {'label':'contrast', 'direction':'None', 'children':[{'start':(25, 0), 'end':(25, 25), 'text':'In melanoma and non small cell lung carcinoma , high basal or induced pAkt protein levels conferred resistance to apoptosis by MEK inhibitors . , ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(25, 26), 'end':(25, 29), 'text':'Here we have shown'}, {'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(25, 30), 'end':(25, 34), 'text':'that in thyroid cancer ,'}, {'start':(25, 35), 'end':(25, 42), 'text':'resistance to apoptosis follows a similar pattern .'}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'LeftToRight', 'children':[{'start':(26, 0), 'end':(26, 10), 'text':'The ATC cell line 8505c demonstrates a remarkable decrease in proliferation'}, {'start':(26, 11), 'end':(26, 18), 'text':'when exposed to BRAF V600E inhibitor PLX4720 ;'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(26, 19), 'end':(26, 31), 'text':'however , unfortunately there is a simultaneous detrimental further increase in pAkt levels'}, {'start':(26, 32), 'end':(26, 39), 'text':'that essentially prevents the initiation of apoptosis .'}]}]}, {'start':(27, 0), 'end':(27, 12), 'text':'Our three-drug combination is likely effective due to effects on multiple fronts .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 0), 'end':(28, 18), 'text':'Most importantly , the inhibition of both pAkt and the MAPK pathway controls the regulatory increase in alternative pathways'}, {'start':(28, 19), 'end':(28, 26), 'text':'caused by the other \'s negated pathway .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(29, 0), 'end':(29, 53), 'text':'In addition , beneficial alterations in the ratios of pro-apoptotic proteins , Bax and Bak , protein expressions and the anti-apoptotic proteins , Bcl-xL , Mcl-1 and cFLIP , favors overcoming the resistance to TRAIL . , Finally , elevations in all three isoforms of Bim contribute to a higher apoptotic response . ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(30, 0), 'end':(30, 4), 'text':'Interestingly , we also found'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(30, 5), 'end':(30, 18), 'text':'that one ATC cell line had an intermediate sensitivity to lexatumumab - SW1736 ,'}, {'start':(30, 19), 'end':(30, 26), 'text':'showing a 24 % cell death response .'}]}]}]}]}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(31, 0), 'end':(31, 18), 'text':'This cell line already has a high Bax and Bcl-xL ratio similar to all the sensitive cell lines ;'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(31, 19), 'end':(31, 22), 'text':'therefore , we hypothesized'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(31, 23), 'end':(31, 35), 'text':'that the resistance to apoptosis was likely due to an increase in pAkt'}, {'start':(31, 36), 'end':(31, 40), 'text':'when exposed to lexatumumab .'}]}]}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(32, 0), 'end':(32, 17), 'text':'Dual-drug combination of a pAkt inhibitor along with lexatumumab triggered increased cell death up to 84 % ,'}, {'start':(32, 18), 'end':(32, 34), 'text':'indicating the importance of inhibition of the pAkt pathway alone in this intermediately sensitive cell line .'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(33, 0), 'end':(33, 3), 'text':'We have shown here'}, {'label':'joint', 'direction':'None', 'children':[{'start':(33, 4), 'end':(33, 14), 'text':'that some thyroid cancer cell lines are sensitive to apoptotic agents'}, {'start':(33, 15), 'end':(33, 25), 'text':'and these agents should be tried clinically in appropriate patients .'}]}]}]}]}]}, {'label':'explanation', 'direction':'LeftToRight', 'children':[{'start':(34, 0), 'end':(34, 22), 'text':'Appropriate patients may include those with no known mutations , high levels of TRAIL-R2 receptor and a high Bax to Bcl-xL ratio ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(34, 23), 'end':(34, 27), 'text':'as these patients have elements'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(34, 28), 'end':(34, 29), 'text':'to suggest'}, {'start':(34, 30), 'end':(34, 40), 'text':'that their tumors will be sensitive to apoptotic agents alone .'}]}]}]}]}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(35, 0), 'end':(35, 33), 'text':'Patients with either activating mutations in the PI3K or MAPK pathways and and or a low baseline Bax to Bcl-XL ratio may need a combination of pro-apoptotic agents such as lexatumumab with kinase inhibitors'}, {'start':(35, 34), 'end':(35, 37), 'text':'to show efficacy .'}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(36, 0), 'end':(36, 12), 'text':'Further studies in genetically engineered models of aggressive thyroid cancer in mice ,'}, {'start':(36, 13), 'end':(36, 23), 'text':'which harbor additional mutations such as p53 and BRAF , ,'}]}, {'start':(36, 24), 'end':(36, 36), 'text':'will undoubtedly shed light on the true efficacy of a combinatorial strategy .'}]}]}]}
